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Introduction. In 2010 more than 3 million children with human immunodeficiency virus (HIV) were living in Sub-Saharan Africa.
The AIDS epidemic has contributed to an abrupt increase of the frequency of Kaposi sarcoma (KS), especially in Southern Africa.
There is a need to describe the clinical features of this disease, itsmanagement, and its outcome inHIV positive children in Southern
Africa. The aim of the study is to describe two different populations with HIV and KS from two African hospitals in Namibia and
SouthAfrica.Material andMethods. A retrospective descriptive study of patientswithKSwhopresented toTygerbergHospital (TH)
andWindhoek Central Hospital (WCH) from 1998 to 2010. Demographic data, HIV profile, clinical picture of KS, and survival were
documented. Results. The frequency of KS declined from 2006 to 2010 in TH but showed an increase in the same period in WCH.
Children in TH were diagnosed at a much younger age than those in WCH (44.2 months versus 90 months). Cutaneous lesions
were the most common clinical presenting feature, followed by lymphadenopathy, intrathoracic and oral lesions. Conclusions. The
clinical characteristics of KS in South Africa and Namibia differ in many aspects between the 2 countries.
1. Introduction
Kaposi Sarcoma (KS) is a low-grade malignant vascular
tumor, with a viral etiology.The typical skin lesions were first
described in 1872 [1] by Moritz Kaposi, a dermatologist from
Hungary. While in most of the world the tumour was seen
only sporadically, in regions from Central and Southern
Africa it was found to be endemic, with incidence comparable
to those of the cancer of the colon in resource-rich countries
[2]. A dramatic increase in the incidence of this malignancy
worldwide was associated with the HIV-AIDS epidemic, to
the extent where KS became one of the AIDS-defining dis-
eases. To distinguish it from the other known forms of the dis-
ease, that is, sporadic and endemic, when associated with
AIDS, KS was said to be epidemic. The etiological agent, KS
herpes virus (KSHV), was only discovered in 1994, as a result
of the work by Chang and collaborators [3], who isolated and
characterized the agent from tissue samples of epidemic KS.
KSHV is endemic in Central and Southern Africa. In
SouthAfrica, a study of seroprevalence of the virus found that
15.9% of healthy children were infected, while in those living
with HIV the prevalence was 28.6% [4]. This prevalence ex-
plains why, with the advent of the HIV epidemic, the incid-
ence of KS soared to previously unknown levels. The odds
ratio for the association of HIV-Kaposi sarcoma inMalawian
children was 93.5 (95% CI 26.9 to 324.4, 𝑃 < 0.001) [5].
The literature on epidemic KS in African children is
scarce; the disease in children is not as well described as in
adults, and the diagnosis, treatment, and prognosis are insuf-
ficiently studied. This situation can be attributed to the rarity
of specialized pediatric oncology services in Southern Africa,
where the AIDS epidemic generates most of the cases of KS.
In SouthAfrican children, an increase was seen from 1998
where one case was diagnosed to 2008 where 26 cases were
documented in the South African Children’s Cancer Registry
(see Table 1).
KS is recognized as an AIDS-defining disease due to the
strong association between the two entities. Sincemore than 3
million children with HIV were living in Sub-Saharan Africa
in 2010, [6], the burden of KS is high in this region. The
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Table 1: Annual numbers of KS recorded in South African Children’s Cancer Registry 1998–2008, mean age, and survival to date.
Year Total cancers KS % of total cancers Mean age (months) Alive % survival
1998 592 1 0.16 62 0 0
1999 575 1 0.17 56 1 100
2000 716 9 1.2 54.3 1 11
2001 648 12 1.8 66.6 10 83
2002 599 14 2.3 78.2 5 35
2003 643 20 3.1 66 13 65
2004 723 24 3.3 79.3 16 66
2005 650 24 3.6 104.1 10 41
2006 592 16 2.7 82.5 13 81
2007 564 13 2.3 82.7 12 92
2008 529 26 4.9 71.7 18 69
Total 6302 160 2.5 73.3 99 61
incidence of HIV in Namibia and South Africa is comparable
[7], but bothNamibia and SouthAfrica are struggling tomeet
the need for ARV therapy in children [8, 9]. South Africa will
fall short of achieving the Millennium Development Goals
with child mortality rates increasing after the layout of these
goals [10].
By the middle of 2011, the number of patients receiving
antiretroviral (ARV) therapy in SA had increased to 1.79 mil-
lion. In 2004 there were 4200 children (below 15 years) on
ARV therapy, compared to 152 000 in 2011 [11]. The relative
low rates of ARV therapy initiation in children are probably
attributed to lower rates of HIV testing in paediatric popu-
lation [12]. There is a disproportionately high incidence of
HIV infection in the Sub-Saharan region.With the increase of
ARV therapy availability, however, secondary malignancies
are on the decline and the incidence of KS is expected to
decrease as well [13].
The incidence of childhood cancer in South African chil-
dren aged 0–14 years ranged between 33.4 and 47.2 permillion
from 2003 to 2007 [14], while in Namibia the incidence was
slightly lower at 29.4 permillion [15].Manymore children are
diagnosed with cancer in developed countries, leading to a
much higher incidence, of 176 per million, in the United
States in 2005 [16]. Since the risk of developing a malignancy
increases with HIV infection, it was expected that the incid-
ence of childhood cancer would soar in countries with a high
HIV burden, but this is not reflected in the available epi-
demiological data from South Africa [17]. There is very little
research published on childhood cancers inNamibia and also
a paucity of studies about treatment and survival of KS in the
paediatric population of Sub-Saharan Africa [13].
This study proposed to analyse and compare Kaposi sar-
coma in children in twoAfrican hospitals: TygerbergHospital
(TH) in South Africa and Windhoek Central Hospital
(WCH) inNamibia. Differences between the 2 groups of chil-
dren diagnosed with KS were looked into in order to provide
better insight into the characteristics of the disease. The vari-
ables of patient demographics, frequency of KS, comorbidi-
ties, management, survival, and HIV profile were assessed to
find differences in this complex disease in the Southern
African region.
2. Patients and Methods
2.1. Site and Study Period. The study evaluated all cases of KS
in two hospitals in the Southern African region: Tygerberg
Hospital (TH) situated in Cape Town in the Western Cape
province of South Africa and Windhoek Central Hospital
(WCH) in the neighboring Namibia, from January 1, 1998
until December 31, 2010.
2.2. Setting. Tygerberg Hospital (TH) is situated in theWest-
ernCape province of SouthAfrica, serving a population of 3.6
million people. It is the largest hospital in the Western Cape
province of South Africa and the second largest hospital in
the country [18].The Department of Paediatrics has 308 beds
and a dedicated hematology oncology unit where an average
of 50 new patients are admitted yearly. All children diagnosed
with a malignancy in the hospital drainage area are referred
from peripheral hospitals and clinics to this tertiary center.
A dedicated paediatric tumor registry has been in exis-
tence for 25 years in South Africa, collecting data from all
cases of malignancy nationwide. Data is sent from all pedi-
atric oncology units and the private sector in the country to
the tumor registry [14]. All units have ethical approval to col-
lect and submit data to the registry through a combined
national ethics agreement.
The prevalence of HIV in children and adults in theWest-
ern Cape province was 3.8% in 2008. The prevalence of HIV
in children (0–15 years) in South Africa was estimated to be
2,5% in the same year [19].
WCH is the only government hospital in Namibia where
childhood cancer cases are treated. There is no dedicated
pediatric oncology tumor registry in Namibia, but the unit
collects data of all new pediatric malignancies presenting to
them.
In 2008, the paediatric oncology units fromboth hospitals
decided to enter into a twinning agreement [20] leading to
close cooperation, which includes discussion of new patients,
adaption of protocols for specific types of malignancies, and
uniformity of treatment regimens, addressing drug availabil-
ity and sharing of data. Both units use similar protocols of
chemotherapy for the treatment of KS.
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2.3. Study Population. The Tygerberg Children’s Cancer reg-
istry was used to obtain information regarding newly diag-
nosed KS in children treated in TH. Data of children treated
for KS in WCH were obtained from the Namibian tumour
registry.
2.4. Inclusion Criteria. All children aged 0–15 years with a
diagnosis of KS were included in the study.
2.5. Exclusion Criteria. Patients older than 15 years were not
included.
Patient folders were reviewed and the following informa-
tion was extracted: age, sex, ethnic group, HIV status, date of
diagnosis of HIV disease, degree of immunosuppression
(WHO criteria), use of antiretroviral therapy, CD
4
count,
HIV viral load values, and date last seen or date when the
patient died. HIV infection was confirmed via the enzyme-
linked immunosorbent assay for HIV-specific antibodies or
PCR-HIV testing in those children below the age of 18
months.The clinical picture of KS including symptoms, signs,
site of disease, histological results, and radiological investiga-
tions was recorded, as well as any comorbid conditions, either
at time of diagnosis or developing thereafter. Uniformity of
histological evaluation was assured, since samples were proc-
essed by pathologists of the National Health Laboratory Ser-
vice (NHLS) in South Africa and Namibia where similar lab-
oratory protocols are applied.Themodality of treatment used
(chemotherapy, ARV therapy, radiotherapy and/or surgery)
was documented.
2.6. Data Management. The data from patients fulfilling in-
clusion criteria were collected on a specifically designed data
collection form and entered into aMicrosoftAccess database.
Confidentiality was assured since the data provided to the
principal investigator was anonymous.
2.7. Statistical Analysis. Treatment outcomes were analyzed
using Statistica software using descriptive analysis and sur-
vival analysis by way of Kaplan-Meier curves. A 𝑃 value of
0.05 or less was regarded as significant.
2.8. Ethical Considerations. Approval was obtained from the
relevant Human Ethics Research Committees of the 2
participating centers (Institutional Review Board Number:
IRB0005239). As this was a retrospective study, consent to
access patient files was obtained through the custodian of the
data and not through individual patient consent.
3. Results
The records of 21 patients were reviewed: 13 from TH and 8
fromWCH.
3.1. Number of New Cases Diagnosed. In the TH cohort, one
case was diagnosed in 1998, with a period of no new cases for
2 years. Most cases were diagnosed during 2000 to 2006, with
onemore child being diagnosed in 2008. From2009 onwards,
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Figure 1: Number of cases newly diagnosed with Kaposi sarcoma in
TH and WCH from 1998 to 2010.
Table 2: Distribution of signs and symptoms in the cases studied.
Symptom or sign Namibia Western Cape Total
Skin discoloration 5 5 10 (38.4%)
Lymphadenopathy 2 4 6 (23%)
Respiratory
distress/shortness of breath 1 3 4 (15.3%)
Oral lesions 1 1 2 (7.6%)
Stridor 0 1 1 (3.8%)
Abscess 1 0 1 (3.8%)
Other 1 1 2 (7.6%)
no new cases were seen until the end of the study period. In
the WCH group, the first case was seen only in 2005. There-
after one case per year was diagnosed, until 2010 when 4 new
cases were identified (Figure 1).
The mean age at diagnosis in TH was 44.2 months (range
10 to 89 months) and in WCH 90 months (range 43 to 141
months).
3.2. Clinical Features. The commonest sign of disease was
skin discoloration (38%; 10/26) with 5 cases each from TH
(38%) and WCH (62.5%). Lymphadenopathy as the present-
ing feature was documented in 6 (23%) cases. The third
most common presenting symptom or sign was respiratory
distress due to intrathoracic KS lesions (4 patients; 15.3%).
Two patients presented with oral lesions (7.6%), 1 with stridor
(3.8%), and 1 with a neck abscess (see Table 2). Some patients
presented with a combination of symptoms and signs.
The skin was the commonest site of disease with more
than half of the patients presenting with skin lesions (13
patients). No specific skin area was more often seen than
others. Lymph node involvement [6] was the second most
common, followed by intraoral lesions/salivary gland
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Table 3: Anatomical distribution of lesions (some patients presented with more than 1 site involvement).
Site of lesions Namibia Western Cape Number of cases
Skin
Facial 2 1 3 (10.3%)
Trunk 0 2 2 (6.8%)
Abdomen 0 2 2 (6.8%)
Leg/foot 2 1 3 (10.3%)
Generalised skin/other 1 2 3 (10.3%)
Total skin 5 8 13 (44.8%)
Intrathoracic 1 3 4 (13.8%)
Lymph nodes 2 4 6 (20.7%)
Intraoral/salivary gland 2 3 5 (17.2%)
Cranium 0 1 1 (3.4%)
Total: 29
involvement [5], intrathoracic lesions [4], and 1 case where
the cranium was involved (see Table 3).
Thediagnosis of KSwas confirmedhistologically in 76.9%
of cases in TH and 88% in WCH by the NHLS laboratory
services. In the remaining cases the diagnosis was made
clinically.
No data was available regarding KSHV status as testing
was not routine practice at these hospitals during the study
period.
All children in the study were HIV positive. In the TH
cohort, 62% (8 patients) were already on ARV therapy at the
time of the diagnosis, while 38% of the WCH group were
receiving ARV therapy at diagnosis. Although KS is a WHO
stage IV defining disease, 27% of children in TH and 87.5% in
WCH were already classified as having stage IV disease prior
to the diagnosis of KS.
Radiological changes ascribed to KS were documented
in 2 cases in the Tygerberg group: one with bilateral pleural
effusions and one with pulmonary and pleural infiltrations.
Both cases were histologically confirmed. InWCH, radiolog-
ical changes were documented in only 1 case of disseminated
KS (right lower lobe opacification and pleural effusion).
3.3. Comorbid Disease. Pulmonary tuberculosis (PTB) was
the predominant comorbid disease present in 38.4% (𝑛 = 5)
of the TH group. No cases of PTB were found in the WCH
population. PTB was diagnosed by a combination of symp-
toms, chest radiographic changes, and sputumor gastric aspi-
rate microscopy and culture.
3.4. Treatment and Outcome. Both TH and WCH used sim-
ilar chemotherapy protocols comprising vincristine (1.5
mg/m2), adriamycin (20mg/m2), and bleomycin (15 iU/m2)
given at 3-4-week intervals for a total of 6 cycles. Local ther-
apy is instituted in cases of limited mucocutaneous disease,
but no case in this study required control locally. Paclitaxel
was not used in any child in this study as no case of relapsed
KS was diagnosed.
3.5. Survival. The survival in WH was 62.5% and in TH
46,1%. In the combined study population 10 patients (48%)
died after an average of 2.4 months. The children that sur-
vived (𝑛 = 11) were followed up for a mean period of 14
months. In the Tygerberg group 3 deaths were attributed to
respiratory insufficiency (intrapulmonary bleeds, direct in-
trathoracic tumor infiltration, and chylothorax). In the WH
group the causes of death were not identified.
In the TH group 2 children suffered disease relapse, 6
months and 29 months after the initial diagnosis. In the first
case of early relapse it was decided to continue with symp-
tomatic treatment only and not to give chemotherapy. This
child never received ARV therapy and died due to complica-
tions of infection. The second patient relapsed in a different
lymph node site. Chemotherapy was recommenced (rescue
protocol) and the patientwas alivewith disease during the last
followup in 2012.
4. Discussion
There are many differences in the clinical presentation of KS
in Southern Africa, notably in the age of the children at diag-
nosis, frequency between the 2 study populations, and profile
of HIV between the 2 countries. Similarities however exist in,
for example, clinical presentation and gender distribution,
which are also in keepingwith theKS that is described in chil-
dren in the rest of Africa [21, 22].
Twenty-one cases of KS were identified in these 2 African
centers over the time period from 1998 until 2010. Children
were diagnosed at a later age in the Windhoek group. This
could reflect a missed group of children with KS at a younger
age in the Namibian population, who did not benefit from
screening programs to facilitate early diagnosis.Themajority
of patients in the Tygerberg group were diagnosed before
2006, in contrast to an increase in KS cases in WCH from
2006 onwards. This difference in patterns could be explained
due to a difference in access to ARV therapy between the 2
study groups. Another possibility is that increased cancer
awareness and screening programs could have led to more
cases diagnosed in Namibia since 2005 as well as better
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referral of HIV positive children to monitor HIV associated
comorbidities and access to ARV therapy.
The annual incidence of cancer in South African children
aged 0–14 years is estimated to be between 33.4 and 47.2 per
million from 2003 to 2007 [14]. In a recent unpublished study
in the same age group, it was found that the incidence in
Namibian children is 29.4 per million [15], although this
might be an underestimation due to the lack of a formal or
consistent cancer registry in Namibia.These figures aremuch
lower than those in developed countries where the incidence
of cancer in children in the United States in 2005 was esti-
mated to be 176 per million [16]. It is likely that a large pro-
portion of childhood cancers are not diagnosed in the Sub-
Saharan African region.
In TH between 1998 and 2010 there were 547 newly diag-
nosed patients with a malignancy (average of 42 malignan-
cies/year). KS represented 2.8% of all malignancies in TH
during this period.This is less than the national SouthAfrican
data where KS comprised almost 5% of the total pediatric
malignancies in 2008 [17].National data showed a progressive
increase in KS frequency in 1998 from 1 patient into the next
decade to 28 patients. In Namibia from 2003 to 2010, 191 new
pediatric malignancies were diagnosed, of which 11 cases
(5.7%) were KS [15], similar to the national South African
data.
This apparent discrepancy in frequency of KS has to be
correlated with the incidence and management of HIV in
both populations. In SouthAfrica theHIV prevalence in chil-
dren below 14 years decreased from 5.6% in 2002 to 2.5% in
2008 [17]. This considerable reduction is largely attributed to
the national Prevention of Mother to Child Transmission
(PMTCT) program and the involvement of the South
African government health services.TheWestern Cape is the
province in South Africa with the lowest prevalence of HIV
infection (in patients ≥ 2 years) at 1.9% in 2005 [18]. In
Namibia the prevalence of HIV infection in children below 14
years was estimated to be 2.1% in 2010/2011 [7]. Estimates of
the HIV epidemic in Namibia in 2008 have suggested that
Namibia has not yet reached its peak prevalence, but it did
have a rapid prevalence growth period, which ended in 2001.
In 2007/2008 77%of new infectionswere amongwomen aged
15–24 years [23], which is a critical area for the country to
address in Prevention of Mother to Child Transmission.
The South African national antiretroviral treatment pro-
gram started in 2004 and has steadily grown. Inequities do
exist between urban and rural areas in the country and there
are also interprovincial differences in achieving ARV therapy
for all in need. In 2010 UNICEF estimated that 54% of chil-
drenwhowere livingwithHIV in SouthAfricawere receiving
ARV therapy [24]. In the Western Cape in 2005, access to
ARV therapy varied from 68 to 85% between primary care
clinics and tertiary hospitals [25].
Coverage of ARV therapy in Namibia increased rapidly
from 3% (2003) to almost 60% (2007) according to national
published data [26], but the majority of children in this study
were already classified as WHO stage IV at the time of diag-
nosis.Thismight represent amissed group of children, which
were not accessing ARV therapy from an early age.
In a review of early infant testing of HIV in Namibia and
3 other countries, Chatterjee et al. [27] reported a very high
rate of loss to followup inNamibia in the postnatal population
who tested HIV-PCR positive.This could in part be an expla-
nation of the difference in age at presentation of KS between
WCH and TH. Our study found that children from WCH
were being diagnosed at almost double the mean age of chil-
dren in TH.
The mainstay of systemic treatment for KS is chemother-
apy and ARV therapy. Local treatment modalities comprise
intralesional vincristine, intralesional interferon alpha, radio-
therapy, and surgery in selected cases [28]. In Sub-Saharan
Africa access to treatment poses more challenges and there
are relatively few studies on treatment response in this region
[13].
Both groups had a significantmale predominance, corres-
ponding to results obtained byAmir et al. in Tanzania [29]. As
in the other African studies, this predominance also tended
to be stronger in younger children [30]. This male predomi-
nance remains unexplained in our study and indeed inAfrica.
Site of presentation of lesions was similar to that found in
other African studies. A Ugandan study of 73 children found
increased lymph node presentation despite higher CD
4
val-
ues. In the South African literature there is a strong focus on
site of presentation. A small case series of 6 South African
children described the radiological findings of pulmonary KS
as an initial site of presentation [31]. Other series looked at
frequency of skin lesions in children with KS and found that
younger children frequently have lymphadenopathy as pre-
senting feature [22]. This study confirmed the importance of
nodal lesions as presenting feature, but cutaneous lesions
were still predominant in both study groups.
This study looked at the difference in clinical presentation
in 2 populations also differing in HIV and ARV therapy pro-
file. Of note is a possible inverse relationship between the use
of ARV therapy and the frequency of KS. As to the clinical
expression of KS there are similarities that also correlate well
with those seen in the rest of Africa.
5. Conclusion
KS is amajorAIDS-defining disease in Sub-Saharan children.
KS in TH and WCH differs in many aspects notably age at
diagnosis, where childrenwere diagnosed at double the age in
the Windhoek group. The number of new cases diagnosed
was found to increase over the study period in WCH while a
decrease was seen in the TH group.This could reflect the dif-
ference in access to ARV therapy in the study populations. A
high mortality rate was found in the combined study group,
probably reflecting the initial lack of availability of ARV ther-
apy. The widespread use of ARV therapy currently is making
major changes in themortality rate. An opportunity exists for
prospective studies to find the best modality of treatment for
KS in the Sub-Saharan region.
6. Limitations
Completeness of the study was limited by incomplete record
keeping particularly chemotherapy use in the Namibian
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population group which used the same treatment protocol as
TH, but it was not always strictly followed. As this is a retro-
spective analytical study, some missing information can be
expected. Followup was incomplete in many patients due to
patient adherence factors, as expected in a thirdworld setting.
The small number of cases recorded overall might not be re-
presentative of the entire population. In Namibia it is esti-
mated that 75% of childhood cancer cases are not seen at the
paediatric oncology unit. A few cases are seen privately and
not documented, but in all likelihood the majority is missed,
which would have a big influence on the frequency.
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